Written by Mark Bern, CPA CFA
This past week I continued the series of articles discussing my Master List. The Master List series is about the process I use to identify quality companies. You are welcome to jump into the series at any place or any time as each articles is written to stand well and make sense on its own, but you also may find it helpful to read the first article in the series, “The Dividend Investors’ Guide to Successful Investing,” which includes a detailed outline of the process of filtering and eliminating companies to narrow the list down to a manageable level. It includes a discussion of each of my ten rules that I apply to rate each company that makes it through the full screening process.
This week’s articles in the series included “The Dividend Investors’ Guide: Part XXIV – America’s Addiction to Drug Companies” and "The Dividend Investors' Guide: Part XXV - America's (Continued) Addiction To Drug Companies". Part XXIV was chosen as Editor’s Picks by the Seeking Alpha staff.
These articles provide my current assessments for each of the respective industries. Featured companies include Abbott Labs (NYSE:ABT), TEVA Pharmaceuticals (NASDAQ:TEVA), AstraZeneca (NYSE:AZN), Bristol-Myers Squibb (NYSE:BMY), Eli Lilly (NYSE:LLY), Merck (NYSE:MRK), Medicis (NYSE:MRX), Novartis (NYSE:NVS), Pfizer (NYSE:PFE), and Sanofi (NYSE:SNY). I also discuss the more notable exceptions and explain why each company failed to make the list. To find out which companies made the list and which ones did not, you’ll have to read the articles linked above.
Finally, Timour and I published an update article about our earlier recommendation on Apple (NASDAQ:APPL) which is up 15% with lower risk than owning the stock.
Looking forward to the coming week I plan to continue my “Master List” series with detailed analysis and explanations of why each company survived my rigorous test. I intend to publish assessments of the Recreation, Restaurant, Entertainment, and a couple of industrial industries in the coming week. There should also be at least two new updates in the enhanced income strategy series this week, most likely on United Technologies (NYSE:UTX) and Microsoft (NASDAQ:MSFT).
Timour and I will be including more articles with specific recommendations as the opportunities present themselves. We hope you will find our analyses and strategies interesting with low risk / high reward potential. We hope you will join us and question our assessments. We always enjoy sharing and learning more from others about the companies we own or want to own. We truly believe that we all benefit from the process. We try to answer every question that is posed in the comments section following each article.
Have a great week and thanks for reading!
Investing articles by Mark Bern
Valuation Plays: Healthcare Stocks by Carla Fried